ArticleOncotarget2020

Baseline neutrophil-to-lymphocyte ratio and c-reactive protein predict efficacy of treatment with bevacizumab plus paclitaxel for locally advanced or metastatic breast cancer.

Yoshimasa Miyagawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.